Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine
|
February 2, 2010
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women
José Garcia-Sicilia, Tino F Schwarz, Alfonso Carmona, et al.
The American Journal of Cardiology
|
August 8, 2009
Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation
Mihael Potocki, Johannes Mair, Michael Weber, et al.
International Journal of Cardiology
|
January 7, 2012
Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011
Christian F Opitz, Rüdiger Blindt, Friedrich Blumberg, et al.
The Journal of Infectious Diseases
|
February 5, 2019
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
Nicolas Folschweiller, Ulrich Behre, Marc Dionne, et al.
The Journal of Infectious Diseases
|
June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
Li-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
International Journal of Cancer
|
August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial
Suzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
Vaccine
|
March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
Elmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Journal of the National Cancer Institute
|
January 30, 2017
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E Tota, Frank Struyf, Marko Merikukka, et al.
BMC Infectious Diseases
|
May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
Xavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine
|
February 2, 2010
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women
José Garcia-Sicilia, Tino F Schwarz, Alfonso Carmona, et al.
The American Journal of Cardiology
|
August 8, 2009
Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation
Mihael Potocki, Johannes Mair, Michael Weber, et al.
International Journal of Cardiology
|
January 7, 2012
Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011
Christian F Opitz, Rüdiger Blindt, Friedrich Blumberg, et al.
The Journal of Infectious Diseases
|
February 5, 2019
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
Nicolas Folschweiller, Ulrich Behre, Marc Dionne, et al.
The Journal of Infectious Diseases
|
June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
Li-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
International Journal of Cancer
|
August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial
Suzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
Vaccine
|
March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
Elmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Journal of the National Cancer Institute
|
January 30, 2017
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E Tota, Frank Struyf, Marko Merikukka, et al.
BMC Infectious Diseases
|
May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
Xavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Page
of 3